The UAE has no abridged verification pathway, and the sponsors who plan around one lose a quarter finding out.
UAE marketing authorisation runs one standard eCTD route through the EDE. The abridged verification pathway sponsors plan around is Saudi Arabia's, not the UAE's.
What a board member needs before the next meeting on this.
- The verification route does not exist here. No UAE instrument or EDE document publishes an abridged pathway for FDA/EMA-approved products. That pathway is the Saudi SFDA's, and it has been carried across the border by consultancy marketing.
- The dossier scales by product class, not by prior approval. A new chemical entity or biologic needs all five eCTD modules; a generic needs a reduced set. That is the only documented route to a lighter file.
- A foreign approval is evidence, not a shortcut. It enters as a legalised CPP, GMP certificates and a declared registration status in the country of origin. The real recognition route is GCC centralised registration.
- Pricing runs 90 working days, double the authorisation. It needs the Pharmaceutical Pricing Committee, an attested price certificate and CIF from reference markets. Sponsors model approval and forget it.
A marketing authorisation is the quiet gate standing in front of every launch plan, every pricing negotiation and every tender bid. Since the end of 2025 that gate has had one keeper, and the sponsors who protect their launch date are the ones who understand what the Emirates Drug Establishment actually is, rather than what the consultancy deck says it is.
One federal authority now, not several desks
At the end of December 2025, federal registration of medical products moved to the Emirates Drug Establishment. Forty-four MOHAP services transferred in full, thirteen are now shared, and five, all narcotics-related, stayed with the ministry. EDE issues marketing authorisations, registers manufacturers, certifies GMP, runs pharmacovigilance and prices the product. MOHAP keeps community and compounding pharmacies. If your regulatory plan still routes a product dossier through MOHAP, it points at a door that no longer opens: the legacy MOHAP drug-registration service pages now return a 404.
There is no verification pathway, and believing there is one will cost you a quarter
The most common error in UAE regulatory planning is the belief that a product already approved by the EMA, the FDA, the MHRA or Japan's PMDA can enter through an abridged or verification route that leans on that prior review. It cannot. No such pathway exists in any UAE instrument, in EDE's service catalogue, or in its own registration user guide. The idea is a transplant from Saudi Arabia, where the SFDA does publish a pathway called Registration According to Verification and Abridged, naming those very regulators. Consultancies have carried the Saudi model across the border in their marketing, and sponsors have built timelines on it. There is a plainer piece of evidence that EDE is not a downstream verifier of Western approvals: in May 2026 it approved AstraZeneca's baxdrostat for uncontrolled hypertension, and the UAE was the first country in the world to do so. A regulator that clears a molecule ahead of the FDA is not waiting on the FDA.
The dossier is an eCTD, and it scales by what the product is
Marketing authorisation runs on an electronic Common Technical Document, and EDE publishes its own eCTD structure. The five modules are the familiar ones, from administrative and prescribing information through quality, non-clinical and clinical study reports. What changes the weight of the file is the product class, not its history abroad. A new chemical entity, a biological or a biosimilar requires all five modules. A generic requires a reduced set. That is the only documented mechanism in the UAE for a lighter dossier, and it is driven by what you are registering rather than by who has already approved it. EDE publishes a 45-working-day service duration for a new drug or biopharmaceutical authorisation, against fees of AED 7,000 for the authorisation itself plus AED 3,500 for analysis, AED 1,000 for the pharmacovigilance plan and AED 500 for the pricing certificate. Read the 45 days for what it is: a service-completion target, not a demonstrated end-to-end approval clock. Registration passes through sample requests, laboratory analysis, bioequivalence and pricing, and each of those can bounce the file back to you. The authorisation, once granted, runs five years.
Where a foreign approval genuinely counts
Prior clearance abroad is not a route. It is evidence, and EDE asks for it precisely. The file needs an original legalised Certificate of a Pharmaceutical Product, valid GMP certificates for the batch releaser and the bulk manufacturer, and a declared registration status in the country of origin naming the authority, the holder and the approval date. For the active ingredient it wants an EDQM certificate of suitability or US-FDA approval of the drug master file. Where a real recognition mechanism does exist, it is regional rather than transatlantic: a product already carrying GCC centralised registration has its UAE expiry set five years from the date of the first GCC certificate, and GCC products are exempt from the requirement to have the price certificate attested by a UAE embassy. If you want the argument that you are not starting from zero, the Gulf Health Council route is the one you can actually make.
The statute offers three doors, and one of them is not yet built
Federal Decree-Law No. 38 of 2024 gives EDE a standard authorisation, a conditional authorisation, and an emergency use authorisation, and MOHAP's own transfer notice confirms EDE now issues all of them. Conditional authorisation is the one nearest to the reliance idea, and it is narrower than sponsors hope: it is aimed at orphan products, rare diseases and products unavailable in the UAE, it turns on an existing approval in a recognised reference country, and it runs for up to a year against a commitment to convert to a full authorisation. No official UAE document publishes the list of which countries count as recognised, so any adviser naming that list to you is filling a gap with an assumption. The law also promises a fast-track route for innovative products of therapeutic importance, and defers the mechanics to executive regulations that, on the public record, have still not been issued. Plan against the standard route. Treat the fast track as an option that does not yet exist.
Pricing is a second clock, and it is twice as long
Approval does not put a product on a shelf. Pricing is a separate EDE service requiring approval from the Pharmaceutical Pricing Committee, completion of every registration requirement, and a price certificate from the manufacturer attested by a UAE embassy in the country of origin. It is externally referenced: EDE wants the CIF of the reference countries in which the product is already marketed, and re-pricing requires reference prices from GCC and European comparators. The published duration is 90 working days, double the authorisation clock, and it is the step launch plans routinely forget. A sponsor who models approval and then discovers pricing is a quarter behind it has not mis-executed. They have mis-sequenced.
Questions before you file
- Has anyone on this file assumed an abridged or verification route, and what is that assumption doing to our timeline?
- Which eCTD module set does our product class actually require, and is Module 3 built to it?
- Do we hold a legalised CPP, GMP certificates for the batch releaser and bulk manufacturer, and the origin-country registration status?
- Is the product GCC-registered, and have we claimed the recognition that carries?
- Have we started the 90-working-day pricing clock in the launch plan, or does the plan end at approval?
Registration is a sequence, like the rest of market access. Build the eCTD to the module set your product class actually demands, assemble the origin-country evidence EDE names rather than the evidence you wish it accepted, file into the standard route, and start the pricing clock knowing it runs long. Do it in that order and your launch window holds. Do it on the assumption of an abridged pathway that does not exist and you will learn the truth one query letter at a time, with the tender you cannot bid still sitting on the desk. Avior builds and manages EDE marketing-authorisation dossiers, from product classification through pricing, and does not sell you a pathway that is not in the rulebook. Bring the product to us before you file: market access and regulatory.